Weekly Cardiology Research Analysis
This week’s cardiology literature highlights precision, physiology, and practical practice-changing RCT evidence. A genomics-enabled substudy of DECLARE-TIMI 58 suggests dapagliflozin yields outsized prevention of heart‑failure hospitalization in carriers of pathogenic cardiomyopathy variants, opening precision prevention opportunities. Long-term FAVOR III China randomized data show QFR-guided PCI reduces 5‑year MI and repeat revascularization versus angiography guidance, supporting physiology‑l
Summary
This week’s cardiology literature highlights precision, physiology, and practical practice-changing RCT evidence. A genomics-enabled substudy of DECLARE-TIMI 58 suggests dapagliflozin yields outsized prevention of heart‑failure hospitalization in carriers of pathogenic cardiomyopathy variants, opening precision prevention opportunities. Long-term FAVOR III China randomized data show QFR-guided PCI reduces 5‑year MI and repeat revascularization versus angiography guidance, supporting physiology‑led revascularization. A high-quality multicenter RCT in JAMA demonstrated no benefit and metabolic harms from routine sodium bicarbonate in in‑hospital cardiac arrest, arguing against its routine use.
Selected Articles
1. Effects of SGLT2 inhibition on incident heart failure in carriers of cardiomyopathy-associated genetic variants.
A whole-exome substudy of the DECLARE‑TIMI 58 randomized trial (n=12,685 sequenced) identified 121 carriers of pathogenic/likely pathogenic cardiomyopathy variants. Dapagliflozin reduced heart‑failure hospitalization much more in carriers (HR 0.18; absolute risk reduction ~13%) than in noncarriers (HR 0.70; ARR ~1%), including carriers without prior HF, suggesting genotype‑guided preventive benefit.
Impact: Provides a compelling precision‑medicine signal by linking rare cardiomyopathy genotypes to markedly greater prophylactic benefit from an established drug class in a large randomized dataset, potentially redefining who should receive early SGLT2 inhibition.
Clinical Implications: Consider prospective genotype screening strategies in high‑risk patients (e.g., older T2D with CV risk) to identify individuals who may derive outsized HF‑preventive benefit from early SGLT2 inhibitor initiation; requires validation in dedicated trials.
Key Findings
- Among 12,685 sequenced DECLARE participants, 121 carried pathogenic/likely pathogenic cardiomyopathy variants.
- Dapagliflozin reduced HHF more in carriers (HR 0.18) than in noncarriers (HR 0.70); interaction P=0.03.
- Absolute risk reduction in carriers was ~13% (including carriers without prior HF), versus ~1% in noncarriers.
2. Angiographic Quantitative Flow Ratio-Guided Coronary Intervention: 5-Year Follow-Up From the FAVOR III China Randomized Trial.
In the multicenter randomized FAVOR III China trial, QFR‑guided PCI (treat if QFR ≤0.80) reduced 5‑year major adverse cardiac events versus angiography guidance (17.5% vs 21.1%; HR 0.80), driven by fewer myocardial infarctions (HR 0.63) and ischemia‑driven revascularizations (HR 0.78). Benefit accrued predominantly within the first 2 years.
Impact: Provides long‑term randomized evidence that physiology‑guided revascularization (QFR) produces durable reductions in MI and repeat procedures, reinforcing implementation of physiology in routine PCI decision‑making.
Clinical Implications: Adopt QFR (or equivalent physiology) to defer treatment of non‑ischemic lesions and focus PCI on functionally significant stenoses; anticipate most outcome gains early and incorporate physiology into PCI workflows and training.
Key Findings
- 5‑year MACE lower with QFR guidance vs angiography (17.5% vs 21.1%; HR 0.80).
- Reduced myocardial infarction (5.8% vs 9.0%; HR 0.63) and ischemia‑driven revascularization (9.6% vs 12.0%; HR 0.78).
- Benefit accrued mainly within the first 2 years; all‑cause mortality similar between groups.
3. Sodium Bicarbonate for In-Hospital Cardiac Arrest: A Randomized Clinical Trial.
A multicenter, double‑blind, placebo‑controlled RCT (913 randomized, primary analysis n=779) found no difference in sustained return of spontaneous circulation between intravenous sodium bicarbonate and placebo (39% vs 37%; RR 1.05; P=0.62). Thirty‑day survival and favorable neurologic outcome were not significantly improved, while alkalosis and hypernatremia were more frequent with bicarbonate.
Impact: A high‑quality, multicenter double‑blind RCT addressing a long‑debated resuscitation practice provides definitive evidence against routine bicarbonate use in in‑hospital cardiac arrest and will likely change protocols and guidelines.
Clinical Implications: Do not use sodium bicarbonate routinely during in‑hospital cardiac arrest; restrict use to specific indications (severe hyperkalemia, tricyclic antidepressant overdose, documented severe metabolic acidosis) and monitor for alkalosis/hypernatremia.
Key Findings
- Sustained ROSC: 39% with bicarbonate vs 37% with placebo (RR 1.05; P=0.62).
- No significant improvement in 30‑day survival or favorable neurologic outcome.
- Higher post‑arrest alkalosis and hypernatremia rates in the bicarbonate group.